Hugel, Inc. 145020
KRX · South Korea · Health Technology
KRW 180,600.00+900.00 (+0.50%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Hugel Inc., a leading global medical aesthetics company publicly traded in South Korea, is accelerating its global skincare expansion by bringing its clinical cosmetics WELLAGE to Sephora, one of the world's leading beauty retailers. Through a strategic partnership with OLIVE YOUNG, Korea's leading beauty and lifestyle retailer, WELLAGE has officially entered the North American market.
Hugel Inc., a leading global medical aesthetics company publicly traded in South Korea, today announced record first-half financial results, with consolidated net sales, operating profit, and net income reaching all-time highs, primarily driven by solid demand for botulinum toxin.
Hugel Aesthetics today announced a major expansion of its U.S. business, marking the next phase of the company's long-term growth strategy. The expansion includes the launch of a dedicated direct sales and field-based medical affairs organization for the #1 best-selling neurotoxin in South Korea for 10 years1, Letybo® (letibotulinumtoxinA-wlbg), and investments in a new consumer K-TOX campaign, medical congress support and clinical evidence generation.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.